患有和未患有胃恶性肿瘤患者门静脉血中凝血和纤维蛋白溶解标志物。
Markers of coagulation and fibrinolysis in portal blood from patients with and without gastric malignancy.
作者信息
Rahr H B, Sørensen J V, Larsen J F, Jensen F S, Bredahl C
机构信息
Dept. of Gastrointestinal Surgery, Aalborg Hospital, Denmark.
出版信息
Scand J Gastroenterol. 1994 Jun;29(6):516-21. doi: 10.3109/00365529409092465.
BACKGROUND
The origin of coagulation and fibrinolysis abnormalities in cancer patients is unknown. The aim of this study was to measure markers of coagulation and fibrinolysis in portal and peripheral blood from patients with and without gastric malignancy.
METHODS
Blood samples were drawn from the portal vein and a peripheral vein in 39 patients undergoing elective gastric surgery, 18 for gastric malignancy and 21 for benign disorders, and analyzed for prothrombin fragment 1 + 2 (F1 + 2), thrombin-anti-thrombin III complex (TAT), fibrinogen and fibrin degradation products (FgDP, FbDP), and fibrinopeptide A (FpA).
RESULTS AND CONCLUSIONS
In portal blood, levels of F1 + 2, TAT, FpA, FgDP, and FbDP did not differ in the two groups. In peripheral blood, levels of FpA and FbDP were higher in cancer patients, but in a multiple regression model malignancy did not contribute significantly to variation in peripheral FpA or FbDP levels. In both groups FpA levels were higher in portal blood than in peripheral blood.
背景
癌症患者凝血和纤维蛋白溶解异常的起源尚不清楚。本研究的目的是测量患有和未患有胃恶性肿瘤患者门静脉血和外周血中的凝血和纤维蛋白溶解标志物。
方法
从39例接受择期胃手术的患者的门静脉和外周静脉采集血样，其中18例患有胃恶性肿瘤，21例患有良性疾病，并分析凝血酶原片段1 + 2（F1 + 2）、凝血酶 - 抗凝血酶III复合物（TAT）、纤维蛋白原和纤维蛋白降解产物（FgDP、FbDP）以及纤维蛋白肽A（FpA）。
结果与结论
在门静脉血中，两组的F1 + 2、TAT、FpA、FgDP和FbDP水平无差异。在外周血中，癌症患者的FpA和FbDP水平较高，但在多元回归模型中，恶性肿瘤对外周FpA或FbDP水平的变化没有显著贡献。两组门静脉血中的FpA水平均高于外周血。
Zotero 插件